Therapeutic strategies for the treatment of spinal muscular atrophy

Jonathan J. Cherry, Elliot Androphy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease that results in progressive dysfunction of motor neurons of the anterior horn of the spinal cord. SMA is caused by the loss of full-length protein expression from the survival of motor neuron 1 (SMN1) gene. The disease has a unique genetic profile as it is autosomal recessive for the loss of SMN1, but a nearly identical homolog, SMN2, acts as a disease modifier whose expression is inversely correlated to clinical severity. Targeted therapeutic approaches primarily focus on increasing the levels of full-length SMN protein, through either gene replacement or regulation of SMN2 expression. There is currently no US FDA approved treatment for SMA. This is an exciting time as multiple efforts from academic and industrial laboratories are reaching the preclinical and clinical testing stages.

Original languageEnglish
Pages (from-to)1733-1750
Number of pages18
JournalFuture Medicinal Chemistry
Volume4
Issue number13
DOIs
StatePublished - Sep 2012

Fingerprint

Spinal Muscular Atrophy
Motor Neurons
Survival of Motor Neuron 1 Protein
Neurodegenerative Diseases
Genes
Therapeutics
Proteins

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Therapeutic strategies for the treatment of spinal muscular atrophy. / Cherry, Jonathan J.; Androphy, Elliot.

In: Future Medicinal Chemistry, Vol. 4, No. 13, 09.2012, p. 1733-1750.

Research output: Contribution to journalArticle

@article{aeb9c5e7071c4b94a49563815f25b095,
title = "Therapeutic strategies for the treatment of spinal muscular atrophy",
abstract = "Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease that results in progressive dysfunction of motor neurons of the anterior horn of the spinal cord. SMA is caused by the loss of full-length protein expression from the survival of motor neuron 1 (SMN1) gene. The disease has a unique genetic profile as it is autosomal recessive for the loss of SMN1, but a nearly identical homolog, SMN2, acts as a disease modifier whose expression is inversely correlated to clinical severity. Targeted therapeutic approaches primarily focus on increasing the levels of full-length SMN protein, through either gene replacement or regulation of SMN2 expression. There is currently no US FDA approved treatment for SMA. This is an exciting time as multiple efforts from academic and industrial laboratories are reaching the preclinical and clinical testing stages.",
author = "Cherry, {Jonathan J.} and Elliot Androphy",
year = "2012",
month = "9",
doi = "10.4155/fmc.12.107",
language = "English",
volume = "4",
pages = "1733--1750",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "13",

}

TY - JOUR

T1 - Therapeutic strategies for the treatment of spinal muscular atrophy

AU - Cherry, Jonathan J.

AU - Androphy, Elliot

PY - 2012/9

Y1 - 2012/9

N2 - Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease that results in progressive dysfunction of motor neurons of the anterior horn of the spinal cord. SMA is caused by the loss of full-length protein expression from the survival of motor neuron 1 (SMN1) gene. The disease has a unique genetic profile as it is autosomal recessive for the loss of SMN1, but a nearly identical homolog, SMN2, acts as a disease modifier whose expression is inversely correlated to clinical severity. Targeted therapeutic approaches primarily focus on increasing the levels of full-length SMN protein, through either gene replacement or regulation of SMN2 expression. There is currently no US FDA approved treatment for SMA. This is an exciting time as multiple efforts from academic and industrial laboratories are reaching the preclinical and clinical testing stages.

AB - Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease that results in progressive dysfunction of motor neurons of the anterior horn of the spinal cord. SMA is caused by the loss of full-length protein expression from the survival of motor neuron 1 (SMN1) gene. The disease has a unique genetic profile as it is autosomal recessive for the loss of SMN1, but a nearly identical homolog, SMN2, acts as a disease modifier whose expression is inversely correlated to clinical severity. Targeted therapeutic approaches primarily focus on increasing the levels of full-length SMN protein, through either gene replacement or regulation of SMN2 expression. There is currently no US FDA approved treatment for SMA. This is an exciting time as multiple efforts from academic and industrial laboratories are reaching the preclinical and clinical testing stages.

UR - http://www.scopus.com/inward/record.url?scp=84865768592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865768592&partnerID=8YFLogxK

U2 - 10.4155/fmc.12.107

DO - 10.4155/fmc.12.107

M3 - Article

C2 - 22924510

AN - SCOPUS:84865768592

VL - 4

SP - 1733

EP - 1750

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 13

ER -